Literature DB >> 29203290

Patterns of locoregional failure in locally advanced non-small cell lung cancer treated with definitive conformal radiotherapy: Results from the Gating 2006 trial.

Emmanuel Jouglar1, Vanina Isnardi2, Dorothée Goulon3, Céline Ségura-Ferlay4, Myriam Ayadi5, Claire Dupuy6, Jean-Yves Douillard7, Marc-André Mahé8, Line Claude9.   

Abstract

PURPOSE: To determine the patterns of locoregional failure (LRF) in patients with locally advanced non-small cell lung cancer treated with definitive radiotherapy (RT). PATIENTS AND METHODS: One hundred and fifty-four patients from the Gating 2006 prospective randomized trial were treated with conformal RT with or without respiratory motion management. For patients with a LRF as first event, treatment planning with simulation CT, pre-treatment 18FDG PET-CT and post-treatment images demonstrating recurrence were registered and analyzed. Measurable LRF was contoured (rGTV) and classified as in-field, marginal, or out-of-field.
RESULTS: Median follow-up was 27.8 months. Forty-eight patients presented with LRF. One-year and 2-year locoregional disease-free survival rates were 77% (95% CI 70-83) and 72% (95% CI 64-79) respectively. 79% of the patients with LRF as first event relapsed within the RT field (55% isolated), 30% had marginal LRF component. Isolated out-of-field failure occurred in only 3% of all patients. The regions of highest FDG-uptake on pre-treatment PET-CT were located within the recurrence in 91% of patients with in-field LRF.
CONCLUSION: In-field failure was the most common pattern of failure. Escalated dose RT with high-dose fractions guided by PET parameters warrants further investigation.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  18FDG PET-CT; Conformal radiotherapy; Dosimetric analysis; Locoregional failure; Lung cancer

Mesh:

Substances:

Year:  2017        PMID: 29203290     DOI: 10.1016/j.radonc.2017.11.002

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Simultaneous integrated boost of intensity-modulated radiation therapy to Stage II-III non-small cell lung cancer with metastatic lymph nodes.

Authors:  Qing-Song Li; Na Liang; Wei-Wei Ouyang; Sheng-Fa Su; Zhu Ma; Yi-Chao Geng; Wen-Gang Yang; Yin-Xiang Hu; Hui-Qin Li; Bing Lu
Journal:  Cancer Med       Date:  2020-09-09       Impact factor: 4.452

2.  Targeting lactate dehydrogenase a improves radiotherapy efficacy in non-small cell lung cancer: from bedside to bench.

Authors:  Yang Yang; Yu Chong; Mengyuan Chen; Wumin Dai; Xia Zhou; Yongling Ji; Guoqin Qiu; Xianghui Du
Journal:  J Transl Med       Date:  2021-04-26       Impact factor: 5.531

3.  Treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis.

Authors:  Tae Hoon Lee; Dong-Yun Kim; Hong-Gyun Wu; Joo Ho Lee; Hak Jae Kim
Journal:  Radiat Oncol       Date:  2021-11-18       Impact factor: 3.481

4.  Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer.

Authors:  Julian Taugner; Chukwuka Eze; Lukas Käsmann; Olarn Roengvoraphoj; Kathrin Gennen; Monika Karin; Oleg Petrukhnov; Amanda Tufman; Claus Belka; Farkhad Manapov
Journal:  Radiat Oncol       Date:  2020-06-09       Impact factor: 3.481

5.  Is clinical target volume necessary?-a failure pattern analysis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy using intensity-modulated radiotherapy technique.

Authors:  Liqing Zou; Li Chu; Fan Xia; Lijun Zhou; Xi Yang; Jianjiao Ni; Junchao Chen; Zhengfei Zhu
Journal:  Transl Lung Cancer Res       Date:  2020-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.